Michael Makris: 3 PTP Haemophilia A in Japan Have Developed FVIII Inhibitors Following Treatment with Efanesoctocog Alfa
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
“Three Previously Treated Haemophilia A Patients (PTPs) in Japan have developed FVIII inhibitors following treatment with efanesoctocog alfa (Altuviiio/Altuvoct). One had severe haemophilia, and the other two had moderate and mild disease. Only 38 patients were exposed to efanesoctocog alfa in the centres these 3 patients were reported from.
This is a very much higher rate than expected, and the reasons are unclear.
Was it chance? We will know very soon, as this drug is now used extensively in PTP haemophilia A patients around the world.”
Title: The First Three Japanese Haemophilia A Patients in Whom Factor VIII Inhibitors Were Observed During Prophylactic Treatment With Efanesoctocog Alfa
Authors: Tazuko Tokugawa, Akihiro Sawada, Satoshi Higasa, Mariko Asai, Hideyuki Nakazawa, Azusa Nagao, Tomoko Yamaguchi, Yushi Chikasawa, Masato Bingo, Takeshi Hagiwara, Katsuyuki Fukutake
Read more posts from Michael Makris in Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026